Home Cart Sign in  
Chemical Structure| 214358-33-5 Chemical Structure| 214358-33-5

Structure of 1400W 2HCl
CAS No.: 214358-33-5

Chemical Structure| 214358-33-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

1400W 2HCl is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase (iNOS).

Synonyms: 1400W (hydrochloride); N-(3-(Aminomethyl)benzyl)acetamidine; 1400W Dihydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 1400W 2HCl

CAS No. :214358-33-5
Formula : C10H17Cl2N3
M.W : 250.17
SMILES Code : CC(NCC1=CC=CC(CN)=C1)=N.[H]Cl.[H]Cl
Synonyms :
1400W (hydrochloride); N-(3-(Aminomethyl)benzyl)acetamidine; 1400W Dihydrochloride
MDL No. :MFCD03428622

Safety of 1400W 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • eNOS

    eNOS, Ki:50 μM

  • iNOS

    iNOS, Kd:<7 nM

  • nNOS

    nNOS, Ki:2 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Macrophages 10 nM 15–18 hours Inhibition of NOS2 activity, reducing Lm spread between macrophages PMC3361567
Aortic rings 744 μM (IC 50) 15 minutes Evaluate the inhibitory effect of 1400W on ACh-evoked cGMP synthesis PMC3594681
Hippocampal slices 150 μM (IC 50) 15 minutes Evaluate the inhibitory effect of 1400W on NMDA-evoked cGMP accumulation PMC3594681
HK-2 cells 100 μg/mL 24 hours To evaluate the effect of 1400W on ROS production in HK-2 cells, results showed that 1400W reduced ROS levels. PMC6976880
Microglia cell line 10, 50, 100, 150 μM 24 hours To confirm the bioactivity of 1400W by determining the suppression of LPS-induced nitrite levels in the media. PMC6768773
N/TERT keratinocytes 1 μM 8 days Inhibition of NOS2 significantly improved the skin barrier formation in the HI 3D model, restoring the lipid barrier. PMC7456239
COH-BR1 cells 10 μM 8-20 hours To evaluate the effect of iNOS inhibition on PDT-induced apoptosis, results showed that 1400W significantly enhanced apoptosis. PMC3594367
MDA-MB-231 cells 10 μM To evaluate the effect of 1400W on PDT-induced apoptosis, results showed that 1400W significantly enhanced apoptosis. PMC3594367

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague Dawley rats Aged rat model Intraperitoneal injection 1 mg/kg Single dose, sacrificed 30 minutes after treatment 1400W markedly improved ACh-induced vasorelaxation (maximal relaxation: 87%±8%, P<0.05), while having no effect on acidified NaNO2-induced vasorelaxation. PMC4012905
Sprague-Dawley rats Insulin resistance model Subcutaneous injection 1 mg/kg Twice daily for 7 days 1400W significantly reversed or attenuated hyperglycaemia, hyperinsulinaemia, insulin resistance (HOMA index), body weight gain, peroxynitrite formation (nitrotyrosine expression) and the up-regulation of biomarkers of inflammation (B1 receptor, carboxypeptidase M, iNOS and IL-1β) in renal cortex and aorta and to some extent in the liver. PMC4882489
Mice Murine model of oxygen-induced retinopathy of prematurity Subcutaneous injection 1 mg/ml Every 8 hours from P12 to P17 To evaluate the potential utility of iNOS inhibitors for therapeutic use in ischemic retinopathy, the results showed that 1400W significantly reduced the size of the central capillary-free area and inhibited intravitreal neovascularization. PMC208943
Mice GSNOR-deficient mice Intraperitoneal injection 1 μg/g Twice daily for 4 days Inhibition of iNOS activity, prevention of AGT depletion, reduction of O6-etdG lesions, and decrease in hepatocarcinogenesis PMC3644027
C57BL/6 mice Systemic Lm infection model Intraperitoneal injection 10 mg/kg Once at 0 and 24 hours post infection Inhibition of NOS2 activity, reducing Lm spread and burden in the liver PMC3361567
Mice High-fat diet-induced obesity model Oral 10 mg/kg Once daily for 28 days To evaluate the effect of 1400W on obesity-induced chronic kidney disease, results showed that 1400W did not significantly improve kidney function. PMC6976880
Wistar rats Hypoxia/re-oxygenation model Intraperitoneal injection 10 mg/kg Single administration, observed for 48 hours and 5 days To investigate the effects of 1400W on lung injury under hypoxia/re-oxygenation conditions in rats. Results showed that 1400W reduced NOx levels, decreased lipid peroxidation, apoptotic cell percentage, and nitrated protein expression, indicating a negative role of iNOS-derived NO in lung hypoxia/re-oxygenation. PMC7067322
C57 BL6/J mice Bleomycin-induced lung injury model Subcutaneous osmotic pump 10 mg/kg/h Continuous administration starting six days prior to ITB Continuous administration of 1400 W via osmotic pump significantly attenuated bleomycin-induced lung inflammation, decreased chemotactic activity of the bronchoalveolar lavage (BAL), and reduced BAL cell count and nitrogen oxide production. Additionally, 1400 W inhibited the formation of S-nitrosylated SP-D (SNO-SP-D) and the structural disruption of SP-D. PMC5059840
Sprague Dawley rats Rat soman (GD) model of epilepsy Intramuscular injection 20 mg/kg Once daily for 2 weeks 1400W significantly reduced GD-induced motor and cognitive dysfunction; reduced nitrooxidative stress (nitrite, ROS; increased GSH:GSSG ratio); reduced proinflammatory cytokines in serum and cerebrospinal fluid (CSF); reduced epileptiform spikes and spontaneously recurring seizures (SRS) in males; reduced neuroinflammatory markers (GFAP + C3 and IBA1 + CD68-positive glia) and neurodegeneration (especially parvalbumin-positive neurons) in some brain regions. PMC10337207
Sprague Dawley rats DFP-induced long-term neurotoxicity model Intramuscular 20 mg/kg Twice daily for the first three days 1400W significantly reduced DFP-induced iNOS and 3-NT upregulation in the hippocampus and piriform cortex, and the serum nitrite levels at 24h post-exposure. 1400W also prevented DFP-induced mortality in <24h. The brain immunohistochemistry (IHC) at 7d post-exposure revealed a significant reduction in gliosis and neurodegeneration (NeuN+ FJB positive cells) in the 1400W-treated group. 1400W, in contrast to the vehicle, caused a significant reduction in the epileptiform spiking and spontaneous recurrent seizures (SRS) during 12 weeks of continuous video-EEG study. PMC6768773
Mice Obesity model induced by high-fat high-sucrose diet Implanted osmotic pump 30 mg/kg/day Continued for 8 weeks Reversed established CMD and oxidative stress, and preserved systolic/diastolic function in mice PMC10264569
MRL/mpj mice Autoimmune disease model Intraperitoneal injection 5 mg/kg Once daily, starting the day before SEB instillation and continuing throughout the experiment 1400W significantly inhibited lipid radical production in the lung, reduced the number of macrophages and neutrophils in BAL fluid, and alleviated inflammatory cell infiltration and collagen fiber synthesis in lung tissue. PMC2700201

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.00mL

0.80mL

0.40mL

19.99mL

4.00mL

2.00mL

39.97mL

7.99mL

4.00mL

References

 

Historical Records

Categories